The investment will be used to help increase enrollment of follicular lymphoma patients in an ongoing Phase I study of Verismo's KIR-CAR therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback